This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
HLA-DR Monoclonal Antibody (LN3), PerCP-Cyanine5.5, eBioscience
catalog :
45-9956-42
quantity :
100 Tests
price :
US 429
clonality :
monoclonal
host :
mouse
conjugate :
PerCP/Cy5.5
clone name :
LN3

The same clone is also sold as:
reactivity :
human
application :
flow cytometry
citations: 34
Reference
Trovato F, Mujib S, Jerome E, Cavazza A, Morgan P, Smith J, et al. Immunometabolic analysis shows a distinct cyto-metabotype in Covid-19 compared to sepsis from other causes. Heliyon. 2022;8:e09733 pubmed publisher
Warmuth S, Gunde T, Snell D, Brock M, Weinert C, Simonin A, et al. Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade. Oncoimmunology. 2021;10:2004661 pubmed publisher
Sureshchandra S, Marshall N, Mendoza N, Jankeel A, Zulu M, Messaoudi I. Functional and genomic adaptations of blood monocytes to pregravid obesity during pregnancy. iScience. 2021;24:102690 pubmed publisher
Mishra A, Lai G, Yao L, Aung T, Shental N, Rotter Maskowitz A, et al. Microbial exposure during early human development primes fetal immune cells. Cell. 2021;184:3394-3409.e20 pubmed publisher
Thome A, Atassi F, Wang J, Faridar A, Zhao W, Thonhoff J, et al. Ex vivo expansion of dysfunctional regulatory T lymphocytes restores suppressive function in Parkinson's disease. NPJ Parkinsons Dis. 2021;7:41 pubmed publisher
Wong S, Oshansky C, Guo X, Ralston J, Wood T, Reynolds G, et al. Activated CD4+ T cells and CD14hiCD16+ monocytes correlate with antibody response following influenza virus infection in humans. Cell Rep Med. 2021;2:100237 pubmed publisher
He C, Sun S, Zhang Y, Xie F, Li S. The role of irreversible electroporation in promoting M1 macrophage polarization via regulating the HMGB1-RAGE-MAPK axis in pancreatic cancer. Oncoimmunology. 2021;10:1897295 pubmed publisher
Fan Y, Sun J, Zhang Q, Lai D. Transplantation of human amniotic epithelial cells promotes morphological and functional regeneration in a rat uterine scar model. Stem Cell Res Ther. 2021;12:207 pubmed publisher
Bharat A, Querrey M, Markov N, Kim S, Kurihara C, Garza Castillon R, et al. Lung transplantation for patients with severe COVID-19. Sci Transl Med. 2020;12: pubmed publisher
Ni H, Zhang L, Huang H, Dai S, Li J. Connecting METTL3 and intratumoural CD33+ MDSCs in predicting clinical outcome in cervical cancer. J Transl Med. 2020;18:393 pubmed publisher
Pierini S, Tanyi J, Simpkins F, George E, Uribe Herranz M, Drapkin R, et al. Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target. JCI Insight. 2020;5: pubmed publisher
Oliveira A, Pereira M, Belew A, Ferreira L, Pereira L, Neves E, et al. Gene expression network analyses during infection with virulent and avirulent Trypanosoma cruzi strains unveil a role for fibroblasts in neutrophil recruitment and activation. PLoS Pathog. 2020;16:e1008781 pubmed publisher
Wardowska A, Smole x144 ska x, Lisowska K, Zdrojewski Z, Piku x142 a M. Dendritic cells' characteristics in patients with treated systemic lupus erythematosus. Acta Biochim Pol. 2020;67:417-429 pubmed publisher
Jørgensen N, Sayed A, Jeppesen H, Persson G, Weisdorf I, Funck T, et al. Characterization of HLA-G Regulation and HLA Expression in Breast Cancer and Malignant Melanoma Cell Lines upon IFN-γ Stimulation and Inhibition of DNA Methylation. Int J Mol Sci. 2020;21: pubmed publisher
Amacker M, Smardon C, Mason L, Sorrell J, Jeffery K, Adler M, et al. New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes. NPJ Vaccines. 2020;5:41 pubmed publisher
Deng Q, Huang S, Wen J, Jiao Y, Su X, Shi G, et al. PF-127 hydrogel plus sodium ascorbyl phosphate improves Wharton's jelly mesenchymal stem cell-mediated skin wound healing in mice. Stem Cell Res Ther. 2020;11:143 pubmed publisher
Sun C, Lan W, Li B, Zuo R, Xing H, Liu M, et al. Glucose regulates tissue-specific chondro-osteogenic differentiation of human cartilage endplate stem cells via O-GlcNAcylation of Sox9 and Runx2. Stem Cell Res Ther. 2019;10:357 pubmed publisher
Esfahani K, Al Aubodah T, Thebault P, Lapointe R, Hudson M, Johnson N, et al. Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation. Nat Commun. 2019;10:4712 pubmed publisher
Lopes D, Oliveira S, Page B, Carvalho L, Carvalho E, Cardoso L. Schistosoma mansoni rSm29 Antigen Induces a Regulatory Phenotype on Dendritic Cells and Lymphocytes From Patients With Cutaneous Leishmaniasis. Front Immunol. 2018;9:3122 pubmed publisher
Balan S, Arnold Schrauf C, Abbas A, Couespel N, Savoret J, Imperatore F, et al. Large-Scale Human Dendritic Cell Differentiation Revealing Notch-Dependent Lineage Bifurcation and Heterogeneity. Cell Rep. 2018;24:1902-1915.e6 pubmed publisher
Brochez L, Meireson A, Chevolet I, Sundahl N, Ost P, Kruse V. Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma. Nat Commun. 2018;9:2921 pubmed publisher
Ventura Ferreira M, Bienert M, Muller K, Rath B, Goecke T, Opländer C, et al. Comprehensive characterization of chorionic villi-derived mesenchymal stromal cells from human placenta. Stem Cell Res Ther. 2018;9:28 pubmed publisher
Terranova Barberio M, Thomas S, Ali N, Pawlowska N, Park J, Krings G, et al. HDAC inhibition potentiates immunotherapy in triple negative breast cancer. Oncotarget. 2017;8:114156-114172 pubmed publisher
Cheung A, Kwok H, Huang Y, Chen M, Mo Y, Wu X, et al. Gut-homing ?42PD1+V?2 T cells promote innate mucosal damage via TLR4 during acute HIV type 1 infection. Nat Microbiol. 2017;2:1389-1402 pubmed publisher
Pathangey L, McCurry D, Gendler S, Dominguez A, Gorman J, Pathangey G, et al. Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens. Oncotarget. 2017;8:10785-10808 pubmed publisher
Sugita S, Iwasaki Y, Makabe K, Kimura T, Futagami T, Suegami S, et al. Lack of T Cell Response to iPSC-Derived Retinal Pigment Epithelial Cells from HLA Homozygous Donors. Stem Cell Reports. 2016;7:619-634 pubmed publisher
Yao Y, Deng Q, Song W, Zhang H, Li Y, Yang Y, et al. MIF Plays a Key Role in Regulating Tissue-Specific Chondro-Osteogenic Differentiation Fate of Human Cartilage Endplate Stem Cells under Hypoxia. Stem Cell Reports. 2016;7:249-62 pubmed publisher
Pike R, Thomas N, Workman S, Ambrose L, Guzman D, Sivakumaran S, et al. PD1-Expressing T Cell Subsets Modify the Rejection Risk in Renal Transplant Patients. Front Immunol. 2016;7:126 pubmed publisher
Brown P, Wong K, Felce S, Lyne L, Spearman H, Soilleux E, et al. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas. Leukemia. 2016;30:605-16 pubmed publisher
Chevolet I, Speeckaert R, Schreuer M, Neyns B, Krysko O, Bachert C, et al. Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma. Oncoimmunology. 2015;4:e982382 pubmed
Chevolet I, Speeckaert R, Schreuer M, Neyns B, Krysko O, Bachert C, et al. Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma. J Transl Med. 2015;13:9 pubmed publisher
Lopes D, Fernandes J, Cardoso T, Bafica A, Oliveira S, Carvalho E, et al. Dendritic cell profile induced by Schistosoma mansoni antigen in cutaneous leishmaniasis patients. Biomed Res Int. 2014;2014:743069 pubmed publisher
Commins S, James H, Stevens W, Pochan S, Land M, King C, et al. Delayed clinical and ex vivo response to mammalian meat in patients with IgE to galactose-alpha-1,3-galactose. J Allergy Clin Immunol. 2014;134:108-15 pubmed publisher
Tian Y, Tao T, Zhu J, Zou Y, Wang J, Li J, et al. Soluble tumor necrosis factor related apoptosis inducing ligand level as a predictor of severity of sepsis and the risk of mortality in septic patients. PLoS ONE. 2013;8:e82204 pubmed publisher
product information
Product Type :
Antibody
Product Name :
HLA-DR Monoclonal Antibody (LN3), PerCP-Cyanine5.5, eBioscience
Catalog # :
45-9956-42
Quantity :
100 Tests
Price :
US 429
Clonality :
Monoclonal
Purity :
Affinity chromatography
Host :
Mouse
Reactivity :
Human
Applications :
Flow Cytometry: 5 µL (0.015 µg)/Test
Species :
Human
Clone :
LN3
Isotype :
IgG2b, kappa
Storage :
4° C, store in dark, DO NOT FREEZE!
Description :
HLA-DR, like other MHC class II molecules, is a transmembrane glycoprotein composed of a 36 kDa alpha chain (DRA) and 27 kDa beta chain (DRB). The alpha chain gene contains 5 exons. Exon 1 encodes the leader peptide, exons 2 and 3 encode the two extracellular domains, and exon 4 encodes the transmembrane domain and the cytoplasmic tail. DRA does not have polymorphisms in the peptide binding part and acts as the sole alpha chain for DRB1, DRB3, DRB4 and DRB5. Within the DR molecule the beta chain contains all the polymorphisms specifying the peptide binding specificities. Hundreds of DRB1 alleles have been described and typing for these polymorphisms is routinely done for bone marrow and kidney transplantation. HLA-DR is expressed primarily on antigen presenting cells such as B lymphocytes, monocytes, macrophages, thymic epithelial cells and activated T lymphocytes. Three loci, DR, DQ and DP, encode the major expressed products of the human class II region. The human MHC class II molecules bind intracellularly processed peptides, present them to T-helper cells, and have a critical role in the initiation of the immune response. HLA and MHC antibodies play a significant role in Immunopeptidomics, facilitating the identification and characterization of neoantigens through high-performance liquid chromatography coupled to tandem Mass Spectrometry.
Format :
Liquid
Applications w/Dilutions :
Flow Cytometry: 5 µL (0.015 µg)/Test
Aliases :
AI323765; BLA-DRB3; BOLA-DRA; BoLA-DR-alpha; BoLA-DRB; BOLA-DRB3; BoLA-DRB3 protein; BoLA-DRB3.2; Bota-DRB01; Bota-DRB02; Bota-DRB04; Bota-DRB07; Bota-DRB21; Bota-DRB22; bovine leukocyte antigen; Cd74; CD74 antigen; CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated); CD74 molecule; Cd74 molecule, major histocompatibility complex, class II invariant chain; class II-associated invariant chain peptide; CLIP; Clone P2-beta-3; DASS-397D15.1; DHLAG; dinucleotide microsatellite; DLA class II histocompatibility antigen, DR-1 beta chain; DLA DRBB1 beta chain; DLA-DR beta; DLA-DRB1; DLA-DRBB1; DR beta-5; DR beta-chain antigen binding domain; DR-16; DR2-beta-2; DR4; DR-4; DR7; DR9; DR-9; DRB; DRB1; DRB1 transplantation antigen; DRB3; DRB4; DRBB1; DR-beta chain; DR-beta chain MHC class II; DRw10; Dw2; DW2.2/DR2.2; E-alpha-f; FLJ51114; FLJ75017; FLJ76359; gamma chain of class II antigens; H-2 class II histocompatibility antigen gamma chain; H-2 class II histocompatibility antigen, E-D alpha chain; H-2 class II histocompatibility antigen, E-K alpha chain; H-2 class II histocompatibility antigen, E-U alpha chain; H-2Ea; H2-Ea; H2-Ea-ps; H2-IE-alpha; histocompatibility 2, class II antigen E alpha; histocompatibility 2, class II antigen E alpha, pseudogene; histocompatibility antigen HLA-DR alpha; histocompatibility complex, class II, DR beta 3; histocompatibility: class II antigens, gamma chain of; HLA class II histocompatibility antigen gamma chain; HLA class II histocompatibility antigen, DR alpha chain; HLA class II histocompatibility antigen, DR beta 3 chain; HLA class II histocompatibility antigen, DR beta 4 chain; HLA class II histocompatibility antigen, DR beta 5 chain; HLA class II histocompatibility antigen, DR-1 beta chain; HLA class II histocompatibility antigen, DR-5 beta chain; HLA class II histocompatibility antigen, DRB1-15 beta chain; HLA class II histocompatibility antigen, DRB1-16 beta chain; HLA class II histocompatibility antigen, DRB1-3 chain; HLA class II histocompatibility antigen, DRB1-7 beta chain; HLA class II histocompatibility antigen, DRB1-9 beta chain; HLADG; HLA-DR antigens-associated invariant chain; HLA-DR1B; HLA-DR3B; HLA-DR4B; HLA-DRA; HLA-DRA1; HLA-DRB; HLA-DRB1; HLA-DRB2; HLA-DRB3; HLA-DRB4; HLA-DRB5; HLA-DR-gamma; human leucocyte antigen DRB1; human leucocyte antigen DRB3; human leucocyte antigen DRB4; human leucocyte antigen DRB5; ia antigen-associated invariant chain; Ia3; Ia-3; Ia-associated invariant chain; Ia-GAMMA; I-E alpha MHC class II; I-Ealpha; II; integral membrane glycoprotein; invariant gamma chain; invariant polypeptide of major histocompatibility complex, class II antigen-associated; INVG34; LA-DRB; leukocyte antigen; leukocyte antigen class II; leukocyte antigen DRB3; lymphocyte antigen DRB1; major histocompatibility complex class II DR-beta chain; major histocompatibility complex, class II, DR alpha; major histocompatibility complex, class II, DR alpha precursor; major histocompatibility complex, class II, DR beta 1; major histocompatibility complex, class II, DR beta 3; major histocompatibility complex, class II, DR beta 4; major histocompatibility complex, class II, DR beta 4 precursor; major histocompatibility complex, class II, DR beta 5; major histocompatibility complex, class II, DRB3; MHC cell surface glycoprotein; MHC class I antigen; MHC class II antigen; MHC class II antigen beta chain; MHC class II antigen BoLA-DRB3; MHC class II antigen DR beta 3 chain; MHC class II antigen DRA; MHC class II antigen DRB1*15; MHC class II antigen DRB1*16; MHC class II antigen DRB1*3; MHC class II antigen DRB1*9; MHC class II antigen DRB3; MHC class II antigen DRB4; MHC class II antigen DRB5; MHC class II antigen E alpha; MHC class II antigen HLA-DR-beta; MHC class II DLA DRB1 beta chain; MHC class II DLA-DRB; MHC class II DLA-DR-beta-1; MHC class II DR beta 1; MHC class II DR beta chain; MHC class II DR beta-chain; MHC class II DR-ALPHA
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com
800-678-5599
headquarters: USA